Introduction
Preliminary phase II clinical studies with recombinant interferon alfa (IFN-␣) suggested this biologic agent had anti-proliferative and anti-tumor effects in patients with both lowgrade and intermediate-grade lymphomas. These studies demonstrated a 15% to 50% objective response rate depending on degree of previous treatment and histology. [1] [2] [3] [4] [5] Further, in vivo studies performed in mice transplanted with human cell lines suggested a synergistic anti-proliferative effect between IFN-␣ and the cytotoxic agents cyclophosphamide and doxorubicin, both effective agents in patients with non-Hodgkin's lymphoma (NHL). (TTF) in patients with low-grade lymphoma following induction of response by multi-agent cytotoxic chemotherapy. [7] [8] [9] [10] A more recently published randomized evaluation of single agent IFN-␣ therapy as maintenance treatment following an intensive multi-drug cytotoxic drug induction approach did not confirm this benefit on TTF. 11 Two randomized studies involving patients receiving both IFN-␣ and cytotoxic regimens, including cyclophosphamide and doxorubicin, as induction therapy have demonstrated an improvement in survival as well as TTF for patients with lowgrade lymphoma. [12] [13] [14] Finally, a meta-analysis of these various trials supports the use of IFN-␣ in addition to anthracyclinebased induction therapy in the treatment of patients with NHL. 15 The ECOG began a randomized trial in the mid-1980s evaluating the use of IFN-␣2a given in combination with doxorubicin, cyclophosphamide, vincristine and prednisone as treatment for NHL. Results from a preliminary analysis, performed 2 years after the study was closed to accrual, indicated that the addition of IFN-␣2a to the four-drug chemotherapy induction regimen resulted in no increase in objective response but did extend TTF and prolonged the duration of complete response. 16 A multivariate analysis of prognostic factors further suggested that IFN-␣2a was associated with prolonged survival; however, a subsequent Kaplan-Meier analysis with 3 years of follow-up demonstrated a trend towards an improved survival from IFN-␣2a, but statistical significance was lacking. 17 With the median follow-up time among survivors now 12 years, updated analyses have been performed and are reported here. Based on recent reports of prolonged TTF and survival for patients with subsets of NHL including low-grade or follicular lymphoma, the value of IFN-␣ in terms of TTF and survival also was explored retrospectively in three histologic subsets of patients treated in this trial.
Methods and patients
As previously reported, 291 patients with stage 3 or 4 moderately aggressive previously untreated NHL were randomized to receive cyclophosphamide, vincristine, prednisone, and doxorubicin: COPA or I-COPA including IFN-␣2a (Roferon-A, Roche Pharmaceuticals, Nutley, NJ, USA) 6 MU/m 2 on days 22-26 of a 28-day cycle for 8-10 cycles. 16 16, 18, 19 A central pathology review was performed; case report forms were independently reviewed and CRs confirmed in this review by strict and uniform adherence to protocol definitions, and sites were queried as appropriate.
Time to treatment failure (TTF) was defined as the interval between the initiation of treatment and the first of disease progression or death. As in the initial analysis in 1992, TTF for patients whose response could not be evaluated or for whom stabilization of disease was the best response (less than 15% of patients on either arm) was censored as of the date those patients were withdrawn from the study. 16 An additional analysis was performed to evaluate the impact of competing causes of death on the comparison of TTF. This analysis also censored the patients who died without progressive disease instead of counting them as failures. Disease-free survival (DFS) was defined as the time from the onset of complete response to the first of relapse or death. Overall survival was defined as the time from date of first treatment to either the last day of contact or the date of death. Survivors were updated annually until death or until lost to follow-up. Kaplan-Meier survival and TTF curves were constructed and compared on two occasions by log-rank test using a two-sided test. 20, 21 Curves were constructed and compared after a median follow-up of 10 years 22 and after 12 years, the latter analyses reported herein. This is an updated and final analysis of a protocol that was closed to accrual in October 1988. The original statistical design did not have a sequential design included.
In addition, TTF and overall survival were compared in three subsets of patients: low-grade lymphoma, intermediategrade lymphoma, and follicular lymphoma. The low-grade lymphoma subset consisted of patients with DWDL, NPDL, and NML; the intermediate-grade group included patients with NH or DPDL; and the follicular lymphoma patients included those with NPDL, NML, and NH. These subset analyses are considered exploratory due to the small numbers of patients in each subset.
Results
As previously reported, 249 of 291 patients enrolled were judged to be evaluable. The majority of inevaluable patients were judged inevaluable based on the central pathology review. One hundred and twenty-seven evaluable patients received COPA, and 122 received I-COPA. As previously reported, the median age in the COPA group was 57 years and in the I-COPA group was 59 years. There were slightly but not significantly fewer women in the I-COPA group (49% vs 43%) and among the patients with a Karnofsky performance status (KPS) of 0 or 1, there were more with a KPS of 0 in the I-COPA group (56% vs 41%). Seventy-five percent of patients in each treatment group had stage IV disease, and approximately two-thirds in either treatment group had no B symptoms. 16 No difference in response to treatment occurred
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Figure 1
Time to treatment failure in the treatment groups (Kaplan-Meier curves).
between the two arms. The overall response rate (PR + CR) was 86% in both arms with 32% of patients in the I-COPA group and 29% in the COPA group achieving a complete response. Toxicity was manageable. Myelosuppression was the most frequently occurring grade 3/4 toxicity. Patients in the IFN-␣2a arm received, cumulatively, 25% less cyclophosphamide and doxorubicin than those treated with COPA as a result of protocol-defined dose reductions in response to myelosuppression. Patients receiving COPA also underwent some dose reduction indicating they were treated to a maximum dose-response as defined by myelosuppression. Patients receiving IFN-␣ received 100% of the projected cumulative dose of IFN-␣, and 85% of all patients completed at least eight cycles of therapy. 16 The median time to follow-up among survivors has now reached 12 years. Approximately 73% of the patients have died: 97 of 127 on COPA and 84 of 122 on I-COPA. The TTF continues to be significantly prolonged among the 249 (127 COPA, 122 I-COPA) evaluable patients (P = 0.008) by the addition of IFN-␣2a to COPA with an estimated median TTF of 1.6 and 2.4 years for patients treated with COPA and I-COPA respectively (Figure 1) . A comparison of the DFS
Figure 2
Disease-free survival for patients achieving a complete response in the treatment groups (Kaplan-Meier curves) (a subset analysis).
Leukemia
Figure 3
Overall survival for the two treatment groups (KaplanMeier curves).
among the 77 patients achieving a CR also revealed a benefit from the addition of IFN-␣2a for the I-COPA patients (P = 0.035, Figure 2 ). Median DFS for the 38 COPA patients was 1.8 years and for the 39 I-COPA patients was 2.7 years. Overall survival was also longer for the 122 patients treated with I-COPA; estimated median survival was 7.8 years for the I-COPA patients as compared to 5.7 years for the 127 patients treated with COPA, but statistical significance was lacking (P = 0.107, Figure 3) .
Among the 97 patients on COPA who have died, 80 had progressive disease whereas 65 of 84 patients receiving I-COPA who have died during follow-up had progressive disease. Seventeen patients on the COPA arm and 19 patients on the I-COPA arm died without documented evidence of progressive disease. The documented causes of death for such patients on COPA included complications directly related to treatment (n = 2), lung cancer (n = 3), cardiac (n = 3), CML (n = 1), and respiratory arrest (n = 1). For patients on I-COPA, documented causes of death included bronchial obstruction due to tumor (n = 1), cardiac (n = 8), and unrelated (n = 2). Cause of death was not documented for an additional 15 patients (seven on COPA and eight on I-COPA). Two of the patients, one in each group, had a second malignancy unrelated to death. One patient receiving I-COPA had prostate cancer, and one patient receiving COPA had a myelodysplastic syndrome. In an analysis to assess the impact of competing causes on the comparison of TTF, the 17 COPA patients and the 19 I-COPA patients who died without evidence of progressive disease were censored at the time of death; this analysis resulted in similar conclusions as the full TTF analysis (P = 0.01).
Exploratory analyses were performed by subset analyses for patients with low-grade lymphoma, intermediate-grade lymphoma, and follicular lymphoma. If it were possible to recover slides for re-review today using current pathologic definitions, it is probable that patients with follicular lymphoma would still be considered as having this type of NHL while variation in diagnosis of patients with DLWD or with DLPD might be noted. The number of patients treated with COPA and I-COPA in each of these subsets is provided in Table 1 . TTF was significantly prolonged by the addition of IFN-␣2a for patients with low-grade lymphoma (P = 0.002; median 1.6 vs 2.4 years; Figure 4 ) and for patients with follicular lymphoma (P = 0.010; median 1.7 vs 2.5 years; Figure 5 ). For patients with 
Figure 4
Time to treatment failure for patients with low-grade lymphoma in the two treatment groups (Kaplain-Meier curves) (a subset analysis).
Figure 5
Time to treatment failure for patients with follicular lymphoma in the two treatment groups (Kaplan-Meier curves) (a subset analysis).
intermediate-grade lymphoma, no significant difference in TTF was detected (P = 0.622); the observed median was 1.6 years for patients treated with COPA and 2.3 years for patients treated with I-COPA. There was no impact demonstrable on survival in any of the three subsets. Median overall survival by subset is provided in Table 2 . 
Discussion
In a large cooperative group trial, the French Groupe d'Etude Lymphomes Folliculaire (GELF) has reported a survival benefit from the use of IFN-␣ administered concurrently with a cyclophosphamide/doxorubicin-based cytotoxic combination for patients with the two follicular low-grade lymphomas, NPDL and NML. 12 This survival advantage was confirmed with longer follow-up. 13 In a small study a group at the Mexican National Cancer Institute has also reported survival benefit from the use of IFN-␣ administered concurrently with a combination of agents including cyclophosphamide and doxorubicin for patients with the three histologic forms of lowgrade lymphoma.
14 In both studies patients received combination chemotherapy which included cyclophosphamide and doxorubicin and, in addition, were randomized to receive IFN-␣ or not as part of induction therapy. The GELF treated patients for 18 months with chemotherapy plus or minus IFN-␣, and then stopped all treatment. 12, 13 The Mexican group treated patients for about 8 months with chemotherapy plus or minus IFN-␣, and then also randomized responders between 1 year of additional IFN-␣ or no maintenance therapy.
14 The ECOG study, also adding IFN-␣ to cyclophosphamide and doxorubicin induction therapy on a randomized basis, demonstrates a 2-year median survival advantage for IFN-␣, but this difference does not achieve statistical significance (P = 0.107).
The ECOG study herein reported accrued patients with the three histologic low-grade subtypes and also included two intermediate-grade subtypes, NH and DPDL. This study design therefore included all three follicular sub-types. We performed subset analyses on patients with low-grade lymphoma (DWDL, NPDL, NML), with follicular lymphoma (NPDL, NML, NH subtypes), and intermediate-grade lymphoma (as represented by patients with NH, DPDL) in order to retrospectively explore for effect of IFN-␣ in these histologic subgroups. There was a beneficial effect on TTF from IFN-␣ in patients with follicular and low-grade subgroups. Although these subset analyses had limited power because of small numbers and the retrospective nature of this subset analysis, the findings lend support to the use of IFN-␣ in addition to cyclophosphamide/doxorubicin-based combination therapy in patients with follicular lymphoma.
Three studies have evaluated the addition of IFN-␣ to single agent alkylating induction therapy followed by a second randomization to IFN-␣ maintenance or not. [23] [24] [25] Three other groups have evaluated the addition of IFN-␣ therapy as maintenance therapy following induction therapy with a variety of cytotoxic drug combinations. [7] [8] [9] [10] [11] Some of these studies demonstrated beneficial effect on time to treatment failure, but none of them have demonstrated benefit on survival.
All of the previously reported trials administered IFN-␣ using a continuous schedule (ie three times a week) while the ECOG administered IFN-␣ using an intermittent schedule. It Leukemia is quite possible that the continuous administration of IFN-␣ is a superior method of administration, but this has not been definitively demonstrated. We utilized the intermittent administration approach in an attempt to avoid as much as possible a concurrent effect on myelosuppression. The cumulative dose of IFN-␣ in other trials has ranged from 24 MU/m 2 /28 days to 60 MU/m 2 /28 days. The cumulative dose of IFN-␣ used in the ECOG trial was 30 MU/m 2 /28 days, intermediate between the two extremes although tending towards the low side. Again, it is possible that the most effective dose of IFN-␣ is the highest dose tolerated, but studies have not been performed to determine this. Although the dose and schedule chosen in this trial for the administration of IFN-␣ is different than for any other trial, the effectiveness of this dose and schedule is demonstrated by its effect on the TTF curves and on cumulative myelosuppression. The dose and schedule chosen for this trial was effective and well tolerated; however, in our opinion, it is probable that a greater impact on survival would be achieved if a more frequent schedule of administration and a higher dose of IFN-␣ were used as was done in the GELF trial.
A meta-analysis of all randomized clinical studies involving the use of IFN-␣ in patients with follicular NHL and reported at the time was presented in 1998. 15 This meta-analysis demonstrated that IFN-␣, administered in conjunction with an anthracycline-based combination of cytotoxic agents, had a beneficial effect on overall survival as well as on TTF. An update of that analysis, which would include the SWOG study recently reported by Fisher et al, 11 is awaited. In conclusion, this study supports pre-clinical data suggesting synergistic effect among the three agents cyclophosphamide, doxorubicin, and IFN-␣. It also supports the use of IFN-␣ as a therapeutic agent in combination with cyclophosphamide and doxorubicin in patients with follicular lymphoma, as is also shown by two other clinical studies.
